In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013

被引：10
|
作者：
Karlowsky, J. A. [1 ]
Walkty, A. J. [1 ]
Baxter, M. R. [1 ]
Adam, H. J. [1 ]
Zhanel, G. G. [1 ]
机构：
[1] Univ Manitoba, Fac Med, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada
来源：
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2014年 / 80卷 / 04期
关键词：
Oritavancin; MRSA; Skin and soft tissue infection; RESISTANT STAPHYLOCOCCUS-AUREUS; INFECTIONS; SKIN;
D O I：
10.1016/j.diagmicrobio.2014.09.003
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Gram-positive pathogens isolated in 15 Canadian hospital laboratories between 2011 and 2013 were tested for susceptibility to oritavancin and comparative antimicrobial agents using the Clinical and Laboratory Standards Institute broth microdilution method. Oritavancin demonstrated in vitro activity equivalent to, or more potent than, vancomycin, daptomycin, linezolid, and tigecycline against the isolates of methicillin-susceptible Staphylococcus aureus (n = 1460; oritavancin MIC90, 0.06 mu g/mL; 99.7% oritavancin-susceptible), methicillin-resistant S. aureus (n = 427; oritavancin MIC90, 0.06 mu g/mL; 99.5% oritavancin-susceptible), Streptococcus pyogenes (n = 132; oritavancin MIC90, 0.25 mu g/mL; 99.2% oritavancin-susceptible), Streptococcus agalactiae (n = 156; oritavancin MIC90, 0.12 mu g/mL; 100% oritavancin-susceptible), and Enterococcus faecalis (n = 304; oritavancin MIC90, 0.06 mu g/mL; 98.7% oritavancin-susceptible) tested. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码：311 / 315
页数：5
相关论文
共 50 条
  • [21] In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic Gram-positive cocci
    Citron, DM
    Kwok, YY
    Appleman, MD
    ANAEROBE, 2005, 11 (1-2) : 93 - 95
  • [22] In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients
    Rolston, Kenneth V. I.
    Wang, Weiqun
    Nesher, Lior
    Shelburne, Samuel A.
    Prince, Randall A.
    JOURNAL OF ANTIBIOTICS, 2016, 69 (05) : 381 - 387
  • [23] Worldwide surveillance of Iclaprim activity: In Vitro susceptibility of gram-positive pathogens collected from patients with skin and skin structure infections from 2013 to 2017
    Huang, David B.
    Charrier, Cedric
    Hawser, Stephen
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2020, 97 (01)
  • [24] In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci
    Hope, Russell
    Chaudhry, Aiysha
    Adkin, Rachael
    Livermore, David M.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 41 (03) : 213 - 217
  • [25] Copper activity against multiresistant Gram-positive cocci isolated in Chilean hospitals
    Kappes, Tomas
    Dominguez, Mariana
    Bello-Toledo, Helia
    Montecinos, Sergio Melia
    Molina, Gisella Riedel
    Gonzalez-Rocha, Gerardo
    REVISTA CHILENA DE INFECTOLOGIA, 2016, 33 (05): : 519 - 523
  • [26] Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006)
    Castanheira, Mariana
    Jones, Ronald N.
    Sader, Helio S.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2008, 61 (02) : 235 - 239
  • [27] Characterization of a Novel Small Molecule That Potentiates β-Lactam Activity against Gram-Positive and Gram-Negative Pathogens
    Nair, Dhanalakshmi R.
    Monteiro, Joao M.
    Memmi, Guido
    Thanassi, Jane
    Pucci, Michael
    Schwartzman, Joseph
    Pinho, Mariana G.
    Cheung, Ambrose L.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (04) : 1876 - 1885
  • [28] Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates
    Canton, Rafael
    Morrissey, Ian
    Vila, Jordi
    Tato, Marta
    Garcia-Castillo, Maria
    Lopez, Yuly
    Gargallo-Viola, Domingo
    Zsolt, Ilonka
    FUTURE MICROBIOLOGY, 2018, 13 (06) : 3 - 19
  • [29] Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA
    Riccobono, Eleonora
    Giani, Tommaso
    Baldi, Giulia
    Arcangeli, Sophie
    Antonelli, Alberto
    Tellone, Valeria
    Del Vecchio, Alessandra
    De Joannon, Alessandra Capezzone
    Rossolini, Gian Maria
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 59 (02)
  • [30] Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014
    Pfaller, M. A.
    Sader, H. S.
    Flamm, R. K.
    Castanheira, M.
    Mendes, Rodrigo E.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2018, 91 (02) : 199 - 204
12345